Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ATF4 | P18848 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715775 | 0.89 | MAPT (0.42) | MAPTPOLBTP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL2809666 | 0.86 | LMNA (0.42) | MAPTTP53SMN1; SMN2L3MBTL1MCHR1 | |
| SCHEMBL2807759 | 0.86 | MCHR1 (0.44) | MAPTPOLBSMN1; SMN2L3MBTL1MCHR1 | |
| SCHEMBL2809050 | 0.85 | ENPP2 (0.43) | MAPTSMN1; SMN2L3MBTL1LMNAKMT2A | |
| SCHEMBL16938617 | 0.84 | MAPT (0.35) | MAPTPOLBTP53LMNA | |
| SCHEMBL16927758 | 0.84 | NFKB1 (0.40) | MAPTHPGDRAB9AUSP2 | |
| SCHEMBL13129773 | 0.82 | ENPP2 (0.41) | MAPTTP53HPGD | |
| SCHEMBL2808900 | 0.81 | ENPP2 (0.41) | MAPTTP53LMNAKMT2A | |
| SCHEMBL16927759 | 0.80 | NFKB1 (0.39) | MAPTUSP2 | |
| SCHEMBL2810118 | 0.79 | EPHX2 (0.42) | MAPTPOLBTP53MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209777-B1 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | claimed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | claimed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | claimed |
| EP-2209777-B1 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2009046842-A2 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240676-A1 | THIAZOLE DERIVATIVES | CCNE2, PKD1, PKD2 | MAPT 1450/4885POLB 2535/4885TP53 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.